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The repurposing of the CRISPR/Cas bacterial defense system against bacteriophages
as simple and flexible molecular tools has revolutionized the field of gene editing. These
tools are now widely used in basic research and clinical trials involving human somatic
cells. However, a global moratorium on all clinical uses of human germline editing has
been proposed because the technology still lacks the required efficacy and safety.
Here we focus on the approaches developed since 2013 to decrease the frequency
of unwanted mutations (the off-targets) during CRISPR-based gene editing.
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INTRODUCTION
Since 2013, the field of gene editing is undergoing a revolution triggered by landmark publications
showing that a ribonucleoprotein involved in the protection of bacteria from bacteriophages can be
used both in vitro (Gasiunas et al., 2012; Jinek et al., 2012) and in human cell lines (Cong et al.,
2013; Mali et al., 2013) to introduce double-strand breaks (DSBs) in DNA at precise locations.
This remarkable defense mechanism is made of two main components, namely, a locus with a
peculiar structure known as “clustered regularly interspaced short palindromic repeats” (CRISPR),
discovered by Mojica et al. (2000) in 20 different microbes in 2000, and a set of CRISPR-associated
(Cas) proteins. In a process known as adaptation, the Cas proteins capture the genetic information
(the “spacers”) from invading bacteriophages and incorporate them into the CRISPR locus. In
the CRISPR system that has been most frequently used for gene editing, the transcript of the
CRISPR locus (pre-crRNA) is processed into CRISPR-RNAs (crRNAs) that will associate with a
partially complementary trans-activator RNA (tracrRNA) and a Cas endonuclease, thus generating
a ribonucleoprotein complex. The crRNA will hybridize to a complementary sequence in the target
DNA named protospacer, provided this sequence is flanked by a 2–6 base pair protospacer adjacent
motif (PAM) recognized by the nuclease, and the Cas endonuclease will then introduce a DSB at a
precise location in the DNA. The targeting of specific sequences via spacers is termed interference.
In eubacteria and notably in archaea, the CRISPR systems are widespread. Three types of systems
have been identified, each defined by a signature Cas gene: Cas3 in type I systems, Cas9 in type
II, and Cas10 in type III. There are excellent articles on the many ways bacteria have diversified
their unique adaptive immune system (e.g., Makarova and Koonin, 2015); here, we discuss mainly
the components of type II, which, due to its simplicity, has been the basis for most gene editing
approaches. For editing purposes, the system was further simplified by the fusion of crRNA with
the tracrRNA, generating a molecule known as single guide RNA (sgRNA) (Jinek et al., 2012). Thus,
a sgRNA and the Cas9 in the cell are sufficient to introduce a DSB.
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Multiple articles have alluded to the path from the early
recognition of CRISPR loci as a set of adaptive immunity
instructions, by Francisco Mojica, to the 2020 Nobel Prize in
Chemistry given to Jennifer Doudna and Michele Charpentier
for their repurposing of CRISPR components as a gene-editing
tool (e.g., Lander, 2016). The explosion of publications using
this flexible, simple, and relatively inexpensive tool and recent
clinical applications based on CRISPR gene editing demonstrate
the impact of this technological breakthrough, but problems
remain. Depending on the context, the technique may lack the
necessary efficiency and sequence specificity to mediate flawless
editing. These concerns are particularly serious in the case of
clinical applications using edited somatic cells (e.g., Lu et al.,
2020; Frangoul et al., 2021) and notably in the case of heritable
genome editing in humans, i.e., changes introduced in sperm,
eggs, or embryos to make genetically modified children, which
has already happened at least once despite the legislation in
many countries barring all clinical uses of germline editing; early
concerns due to the simplicity and potential of the technique
followed by a call for a moratorium on germline genome editing
signed by prominent figures in the field illustrate the ongoing fear
(Baltimore et al., 2015; Lander et al., 2019).
Here we will focus exclusively on one of the main problems of
the technique: the unwanted changes in the genetic information
that the CRISPR editing produces outside of the target region(s)
(Figure 1). These undesired alterations are known in the field
as “off-targets.” We will review why off-targets are observed
when Cas9-mediated gene editing is used, the several strategies
developed to decrease them (Figure 2), and the off-targets of
other competing editing technologies, providing quantitative
comparisons when the data are available.
CLUSTERED REGULARLY
INTERSPACED SHORT PALINDROMIC
REPEATS/Cas9 ON- AND OFF-TARGET
ACTIVITY
Most CRISPR-based editing involves DNA repair. Targeted DSBs
were found to increase the integration frequency of reporters
with homology arms by orders of magnitude (Rouet et al., 1994),
which has been explored by several gene-editing techniques based
on programmable nucleases, of which CRISPR editing is the
latest example. In the case of knockins, the DSB will recruit
the high-fidelity homology-directed repair (HDR) machinery to
integrate a piece of genetic information introduced in the cell
as a template (Heyer et al., 2010). In the case of a knockout,
no template is introduced, and most strategies are based on the
action of the error-prone non-homologous end-joining (NHEJ),
which can repair the DSB in a flawed way, introducing deletions
or insertions (indels) (Pardo et al., 2009) that lead to frameshifts
and, consequently, transcripts that are targeted by the non-sense-
mediated mRNA decay (NMD) surveillance pathway.
Unfortunately, the crRNA pairing with the protospacer only
involves 20 base pairs and lacks the necessary complexity to
always ensure a single hit in a genome with more than 3 billion
base pairs, such as the human genome. Adding to the problem,
the pairing of the 20-bp region does not require 100% identity
and tolerates mismatches, which vastly increases the number
of potential off-targets (Figure 1). Several studies have focused
on the promiscuous nature of the binding of the Cas9:sgRNA
complex to DNA, providing mechanistic insights on the off-
target Cas9 activity. Early work on human cells revealed that
a DSB could occur even when the PAM-distal region of the
protospacer has up to five mismatches with the sgRNA (Fu et al.,
2013; Hsu et al., 2013). Since these initial studies, it has been
further found that the specificity of Cas9 is heavily determined
by the first 7–12 bp-long seed sequence proximal to the PAM
(Jiang and Doudna, 2017). Crucially, the DNA interrogation
mechanism by Cas9 was later elucidated, revealing the PAM’s
absolute requirement for double-stranded DNA unwinding, and
the posterior evaluation of sequence similarity between the target
sequence and sgRNA. These molecular insights made it clear
that off-target activity should only be encountered in PAM-
adjacent sequences (Sternberg et al., 2014). In 2014, genome-
wide chromatin-immunoprecipitation sequencing (ChIP-seq)
was used to map the binding sites of catalytically inactive
Cas9 (dCas9). The results validated the PAM requirements for
Cas9 binding and showed that targeting was enriched in open
chromatin loci, indicating the chromatin structure as one factor
mediating Cas9 sequence recognition (Kuscu et al., 2014). The
latter finding was independently validated afterward (Yarrington
et al., 2018; Janssen et al., 2019).
OFF-TARGET PREDICTION TOOLS
It is not possible to completely avoid off-targets, but selection
of the on-target sgRNAs with the highest efficiency and the
smallest number of off-targets or without off-targets in critical
genomic regions, such as coding sequences, can reduce off-
target frequency/effects. As of the writing of this review, 49
online tools can predict off-target sequences and score the
gRNA efficiency for on-target activity (Torres-Perez et al., 2019).
These tools can be alignment- or scoring-based. Alignment-
based methods rely on the sequence similarity search of the
sgRNA sequence in a given genome and, according to the
mechanistic studies on Cas9-mediated DSB sequence recognition
requirements, off-target sites are determined. Bowtie, a pre-
CRISPR-era NGS-based alignment tool (Langmead et al., 2009),
allows very few mismatches in the sgRNA seed sequence, making
off-target prediction incomplete (Doench et al., 2016). However,
using the Bowtie algorithm, with modifications, the CCTop tool
finds off-targets with up to five mismatches in the protospacer
sgRNA sequence, and scores each sgRNA according to the
likelihood of a stable sgRNA/DNA heteroduplex (Stemmer et al.,
2015). CasOFFinder includes no limits in the mismatch base
number (Bae et al., 2014). Both tools allow the choice of PAM
sequences for different programmable nuclease platforms, but
compared to experimentally generated off-targets, the CCTop
and CasOFFinder tools only identify a subset of sites, suggesting
that sequence similarity alone is not sufficient for complete off-
target prediction (Cameron et al., 2017). Scoring-based methods
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FIGURE 1 | The Cas9:sgRNA ribonucleoprotein complex targets the genomic DNA when present in the cell nucleus. It will target PAM-adjacent sequences and may
encounter several potential recognition sites. If there is a perfect base pairing between the target DNA and the sgRNA, a DSB is induced by Cas9. If there is a
mismatch between the sgRNA and the DNA sequences present within the first 7–12 bp (proximal to the PAM) segment, the base pairing will not be sufficient to
induce a DSB. If one or more mismatches between the DNA and sgRNA sequences are found in the PAM-distal (5′ end of the sgRNA) nucleotides, a DSB can be
induced by Cas9, leading to off-target activity. The scenario of sgRNA sequence-independent off-targets is not depicted.
include sgRNA whole-genome alignment and an additional score
for each possible sgRNA. According to empirical data, scores are
usually attributed to genome context (open vs. closed chromatin,
for instance) and specific mismatch type or location within
the protospacer. The MIT score, proposed in the early days
of the CRISPR era, was derived from the activity evaluation
of > 700 sgRNAs in > 100 predicted off-target loci. The data
were used to determine a weight matrix for each mismatch
position (Hsu et al., 2013). This score was integrated into several
tools, such as CHOPCHOP (Labun et al., 2016) and CRISPOR
(Haeussler et al., 2016). Another widely used scoring method
is the Cutting Frequency Determination (CFD), which was
generated from the analysis of the on and off-target activity of
a > 27 k sgRNA library. The library included a primary set
of all sgRNAs against Cd33, regardless of PAM, combined with
variant sgRNAs having 1-nucleotide insertions, deletions, and
mismatches (Doench et al., 2016). The CFD score is included
in the CRISPRScan (Moreno-Mateos et al., 2015), CRISPOR
(Haeussler et al., 2016), and GuideScan (Perez et al., 2017)
tools. Finally, using empirical datasets, machine-learning-based
tools have also been developed. DeepCRISPR provides off-
target prediction considering epigenetic sequence factors and was
reported to outperform the other available off-target prediction
tools (Chuai et al., 2018). Scanning a given single exon from
each of 36 different genes, it can be seen that there are major
differences in the sgRNA choices of six widely used online tools
(Figure 3), which means that these programs also select different
constellations of off-targets, particularly in knockout projects,
which impose fewer constraints in the selection of the sgRNAs
than knockin projects. Systematic comparisons between the tools
and methods for sgRNA determination are still needed.
DETECTION OF OFF-TARGETS: BIASED
AND UNBIASED METHODS
Bacteria have evolved for millions of years with their
CRISPR systems. In contrast, human cells were exposed
to Cas9 during evolution, and their genomes are orders of
magnitude larger than those of bacteria. Thus, CRISPR off-
target events are unavoidable in large Eukaryotic genomes,
and their detection poses several technical challenges.
Two types of detection methods have been used. In the
biased methods, only sequences predicted by the in silico
tools mentioned above or resulting from empirical studies
are analyzed. This produces a relatively small set of
potential off-target sequences that several methods can
then analyze, including the detection of mispairings in
the amplified region by the T7 endonuclease I, Sanger
sequencing, Next Generation Sequencing (NGS), or off-target
reporters (Table 1).
Given the current limitations and disparities in the results
produced by the in silico approaches to detect the efficiency
of the sgRNAs for their on-targets, the prediction of the off-
targets is even more problematic, due to the increased number
of variables and the lack of data for most species on the
epigenetic features that are known to influence the specificity
and efficiency of CRISPR editing, explored by programs such
as DeepCRISPR (Chuai et al., 2018). Thus, the strategies of
the second type, known as the unbiased methods, have gained
crucial importance. The unbiased methods teach us about the
best criteria to identify off-targets and provide a comprehensive
collection of the real off-targets. There is now a plethora of
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FIGURE 2 | Strategies to decrease CRISPR/Cas9 off-target activity. The procedures to mitigate undesired CRISPR/Cas9 gene editing start (I) in silico, namely in the
design of the sgRNAs. Several bioinformatic tools are available to determine the predicted off-targets of a given sgRNA, and one should choose a sequence that has
high theoretical on-target activity and a low probability of generating off-target DSBs. The second step is (II) the delivery type of the CRISPR/Cas9 system players,
which determines how long the cell becomes exposed to the RNP complex. Furthermore, (III) the engineering of the sgRNAs is an efficient strategy to decrease
off-target activity. One additional major focus has been to (IV) engineer the highly specific SpCas9 forms with decreased off-target activity. Moreover, (V) the SpCas9
orthologs have a repertoire of PAM specificities, which increases the options for suitable sgRNA and may also decrease the off-target activity if the complexity of the
PAM is higher than that of SpCas9. (VI) Cas9-mediated DSBs may be repaired by the HDR or NHEJ pathways, which generate distinct repair products. As the HDR
repairs the DNA damage restoring the original sequence, it has been argued and shown that the repair of off-targets by this pathway does not generate undesired
gene edits. HDR repair is promoted either by pharmacological inhibition or cell-cycle-regulation. More recently, the use of Base Editors (VII), where a catalytically
dead Cas9 or a Cas9 nickase is fused to a cytidine deaminase that drives a single nucleotide modification, has the potential to reduce off-targets, due to sequence
requirements and the lack of DSBs. The blockage of off-targets by GUARD RNAs (VIII) has also been shown to reduce off-targets of Cas9. Finally, (IX) the chromatin
organization manipulation may skew the off-target activity.
techniques that we divide here into in vitro, ChIP-seq, and DSB-
capture methods (Table 1).
One of the in vitro methods is Digenome-seq, in which the
targeted cells are subjected to whole-genome sequencing. The
genomic DNA is digested in vitro with the ribonucleoprotein
complexes (RNPs) to maximize the detection of off-targets,
which are then detected by NGS as fragments with identical 5′
ends, allowing the detection of off-targets with a 0.1% or lower
frequency of indels (Kim et al., 2015). The authors concluded
that Cas9 could be highly specific, inducing indels at only a
few off-targets. Another in vitro method providing the same
type of data is SITE-Seq, which is based on the cleavage of
genomic DNA by an RNP and then the tagging, enrichment,
and sequencing of the fragments (Cameron et al., 2017). One
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FIGURE 3 | sgRNA choice comparison between available online tools. Using
a total set of 36 exons from different genes with an average size of 386 ±
530 bp (list below), the top 10 sgRNA of the CCTop, CasOFFinder,
CRISPRScan, GuideScan, CHOPCHOP, and DeepCRISPR were determined.
Afterward, the common top sgRNAs between any two tools were identified for
each, and the mean number of common guides is shown in the matrix based
on a heatmap. Each square represents the comparison of the corresponding
horizontal and vertical position. The different choice of sgRNAs between the
available tools for a given genomic region target is associated to the choice of
different collections of potential off-targets. The list of genes used: SPHK1
(Hs), SPHK2 (Hs), IL7RA (Hs), IDE (Hs), HLA (Hs), BLM (Hs), GUSB (Hs),
AZIN1 (Hs), ADRA2C (Hs), ADRB2 (Hs), MAPT (Hs), SMAD3 (Hs), EIF2AK4
(Hs), MVK (Hs), Anxa1 (Mm), Adra2c (Mm), KLHL (Hs), Mlh1 (Mm), Msh6
(Mm), KRAS (Hs), DHX37 (Hs), RYR2 (Hs), NR3C1 (Hs), ODF2 (Hs), Hnf4a
(Mm), Braf (Mm), POLMU (Hs), LYPLA2 (Hs), PPT1 (Hs), ESRRA (Hs), TCRB
(Hs), BTBD9 (Hs), GALNT1 (Hs), MAN2A (Hs), and ST6GAL1 (Hs).
of the limitations of Digenome-seq and SITE-Seq is the high
background of random DSBs. Thus, Circularization for In vitro
Reporting of CLeavage Effects by sequencing (CIRCLE-seq)
was eventually developed to solve this problem. Essentially,
in this in vitro method the DNA is first circularized and
then linearized by the RNP being tested. Since only these
linearized products will be sequenced, the background of RNP-
independent genomic breaks previously present is vastly reduced
(Tsai et al., 2017).
ChIP-seq using a catalytically inactive Cas9 revealed that the
potential off-targets are enriched in the open chromatin regions,
and the number of off-targets varied widely from around 10 to
over 1,000 depending on the sgRNA used (Kuscu et al., 2014).
DISCOVER-Seq is another ChIP-seq approach, but based on the
tracking of the MRE11, a repair factor that is recruited to the Cas9
cut site and allows the identification of the nuclease cutting site
with a single-base resolution (Wienert et al., 2019).
Unlike the ChIP-seq methods, the key step in GUIDE-
seq is the ligation to the DSBs of double-stranded
oligodeoxynucleotides in live cells expressing the RNP followed
by NGS (Tsai et al., 2015). It was reported that the majority of
off-targets detected had not been detected by the computational
methods available at the time. Another method based on the
capture of the RNP-dependent DSBs is High-Throughput Gene
Translocation Sequencing (HTGTS), which was originally
developed to detect DSBs introduced by natural processes in
lymphocytes (Hu et al., 2016). Unlike the previous method, in
HTGTS the DSBs to detect are captured in vivo by a single DSB
generated in the genome by a meganuclease. One additional
DSB-capture method is based on the observation that the linear
double-stranded genome of an integrase-defective lentiviral
vector (IDLV) incorporates preferentially into DSBs by NHEJ.
A lentivirus encoding a puromycin-resistant gene was used to
tag in vivo the DSBs introduced by distinct RNPs and, after
selection of the cells with puromycin, the integration sites of the
lentivirus were mapped (Wang et al., 2015). Another technique,
Breaks Labeling In Situ and Sequencing (BLISS), directly tags
the DSBs in fixed cells or tissue sections (Yan et al., 2017). It
should be noticed that these capture methods do not distinguish
between the RNP-dependent breaks and other DSBs, which
explains why there was only a 2–3 fold increase in the number of
puromycin-resistant colonies relative to the control in the IDLV
study (Wang et al., 2015). It is only by mapping the breaks to the
genome more likely to be associated with the RNP activity that
the off-targets are identified, which makes these capture methods
not absolutely unbiased.
Verification of in vivo off-targets (VIVO) is a final method
worth mentioning because it combines the specificity of
the in vitro CIRCLE-seq to identify potential off-target sites
with the NGS analysis of these regions in cells exposed to
RNPs (Akcakaya et al., 2018). Interestingly, the study found that
depending on the choice of the sgRNA, the off-targets could be
substantial in number or undetectable.
STRATEGIES TO DECREASE
OFF-TARGET ACTIVITY BASED ON
sgRNA ENGINEERING
Computational prediction of off-target activity is the first step
in minimizing these undesired events. Additional experimental
approaches have been proposed to ablate Cas9 off-target activity,
based on several aspects of the CRISPR/Cas9 genome editing
biology. The first evidence on the sgRNA-target DNA base
pairing requirements, mentioned above, inspired initial work
on off-target minimization. It was reasoned that truncated
sgRNAs would reduce the RNA-DNA interface, increasing the
Cas9/sgRNA complex binding sensitivity to mismatches, thus
reducing off-target events. The use of truncated sgRNAs reduced
the DSB generation in off-target sites by 5,000-fold compared
to full-length ones (Fu et al., 2014). Reducing the length of
the sgRNA also increases the potential number of off-targets,
but 97 potential off-targets were analyzed, including all with a
single mismatch, and only one had a detectable number of off-
targets. Furthermore, the addition of two guanine nucleotides
to the 5′ end of the complementary sequence of the sgRNA
improved target specificity, reducing off-target events (Cho et al.,
2014). More recently, the addition of a hairpin to the 5′ end
of the sgRNA was shown to elevate the energetic requirements
for sgRNA/target DNA base pairing, improving the specificity of
the Cas9/sgRNA complex, thus decreasing the off-target activity
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TABLE 1 | Summary table of the methods currently available to detect off-target activity in gene editing applications.
Methods References
Biased Advantages Disadvantages
T7 endonuclease I Fast and easy to use Very limited to predict off-targets
Sanger sequencing Relatively fast and easy to use Limited to amplified regions and




High coverage and resolution Not targeted to off-target discovery
(unless it’s a whole-genome
approach)
Off-target reporters Precise measure of off-target activity Restricted to the reporter sequence
Unbiased
In vitro
Digenome-seq Detection of off-targets with a 0.1% or lower frequency of
indels
High background of random DSBs,
requires reference genome,
expensive
Kim et al., 2015
SITE-Seq Allows the recovery of both high- and low-cleaveage
off-target sites
High background of random DSBs Cameron et al., 2017
CIRCLE-seq Background of RNP-independent genomic breaks is vastly
reduced
Limited to cells that can be
transfected with the GUIDE-seq
dsODN tag




Excellent coverage Detects only dCas9-associated
off-targets
Kuscu et al., 2014
DISCOVER-Seq Allows the identification of the nuclease cutting site with a
single-base resolution
Detects only off-targets associated
with adenoviral-delivered Cas9
Wienert et al., 2019
DSB capture
GUIDE-Seq Can identify off-targets that are not detected by existing
computational methods or CHIP-seq
Efficiency is limited to chromosomal
relaxation
Tsai et al., 2015
HTGTS Able to detect a wide range of broken end structures with
nucleotide-level resolution. Sensitive and reproducible,
relatively inexpensive and scalable
Only detects DSBs that translocate Hu et al., 2016
IDLV Efficient detection of off-targets in primary cells Lower sensitivity than other
methods
Wang et al., 2015
BLISS Allows the direct labeling of DSBs in fixed cells or tissue
sections on a solid surface, highly sensitive, easy scalability,
and multiplexing
Detection of off-targets present only
in the labeling period
Yan et al., 2017
VIVO Detects in vivo off-target effects of gene-editing nucleases.
Can be used with Cas9 variants and other Cas orthologs
− Akcakaya et al., 2018
(Kocak et al., 2019). The chemical modification of the ribose-
phosphate backbone of a specific site within the sgRNA was also
described to reduce off-targets (Ryan et al., 2018).
ENGINEERED Cas9 VARIANTS TO
DECREASE OFF-TARGET ACTIVITY
Streptococcus pyogenes Cas9 (SpCas9) is the most broadly used
Cas9. Initial studies employed mutated SpCas9 proteins, that
work as nickases (nCas9), cleaving only one strand of DNA. To
increase the complexity of the sequence that defines the target
region, two RNPs with proximal protospacers would theoretically
minimize off-target activity. In fact, two sufficiently close DNA
strand nicks were able to generate DSBs (Ran et al., 2013) and
were shown to decrease off-target activity (Ran et al., 2013;
Shen et al., 2014). The use of two nCas9s improved specificity,
since the off-targets for each sgRNA are unlikely to be close to
each other and isolated off-target nicks are easily repaired. Two
back-to-back papers (Guilinger et al., 2014; Tsai et al., 2014)
also explored the concept of DSB generation dependent on two
sgRNAs using a dCas9 fused to a FokI nuclease to induce DSBs. In
both studies, there was a substantial decrease in off-target activity
when the dCas9-FokI fusions were used. The peptide linkers
between dCas9 and FokI nuclease were then improved, and
by deep sequencing no detectable off-target activity was found.
Following these studies, chimeras of RNA-guided FokI nucleases
have been produced that maintain high editing efficiency, solving
the main limitation of this system (Havlicek et al., 2017).
One of the key developments for improved Cas9 proteins
was its crystal structure resolution when in complex with the
sgRNA and target DNA (Nishimasu et al., 2014). With the protein
conformation information, it was possible to determine potential
sites for the splitting of Cas9, enabling the controlled reassembly
and activation of the protein. The use of this strategy showed
no detectable off-target modifications by sequencing of predicted
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sites but diminished on-target activity (Zetsche et al., 2015b). The
crystal structure also enabled the detection of a positively charged
groove responsible for stabilizing the non-targeted DNA strand
in the Cas9:sgRNA/DNA complex. Upon charge neutralization
of the protein domain, Cas9:sgRNA binding to double-stranded
DNA was more dependent on Watson-Crick base pairing
between the sgRNA and the target DNA sequence, thus reducing
the off-target activity to levels undetectable by whole-genome
deep sequencing. This structure-guided engineered Cas9 was
coined “enhanced specificity” SpCas9 (eSpCas9) (Slaymaker
et al., 2016). In the same year, several amino acids of SpCas9 were
identified to have non-specific DNA contacts with the target DNA
strand, and once mutated, a decreased tolerance for protospacer
mismatches was observed. Moreover, using GUIDE-seq (Tsai
et al., 2015), off-target activity was not detected for the mutated
SpCas9, named high-fidelity SpCas9 (SpCas9-HF1) (Kleinstiver
et al., 2016a). Although highly specific, these two engineered
SpCas9 proteins showed reduced on-target activity in some target
genes (Kim S. et al., 2017). The mechanism for the increased
specificity of these highly specific SpCas9 variants was later found
to be due to raised thresholds for conformational activation upon
DNA binding of these proteins. With this knowledge, a hyper-
accurate Cas9 (HypaCas9) variant was developed that shows
improved on-target specificity without compromising on-target
activity (Chen et al., 2017). The Sniper-Cas9 variant was then
developed using a directed evolution approach, revealing on-
target activity level similar to that of SpCas9 and better specificity
than the other high-fidelity engineered variants (Lee et al., 2018).
Finally, a HiFi Cas9 variant was generated using an unbiased
bacterial screen. It contains a single point mutation in the SpCas9
backbone that increases the on-target activity compared to the
other rationally engineered variants, maintaining no detectable
off-target activity (Vakulskas et al., 2018).
The race for the generation of Cas9 variants with the desired
high on-target and negligible off-target activity appears to still be
on a fast pace (Table 2). Further detailed comparisons between
these and future engineered Cas9 variants are needed across
genomes, delivery methods, and cell types.
ON- AND OFF-TARGET ACTIVITY OF
Cas9 ORTHOLOGS
Since the early days of CRISPR research in bacteria, it was
clear that this molecular immune system is ubiquitous (Gasiunas
et al., 2020). As Cas9 orthologs began to be discovered and
characterized, new tools were developed to induce programmable
DSBs, with key differences from the SpCas9-based ones. The
SpCas9 ortholog derived from S. aureus (SaCas9) has the
advantage of being encoded by a small gene (SpCas9 4.1 kb,
SaCas9 3.2 kb), which allowed the use of an adeno-associated-
virus (AAV) vector for more efficient in vivo or ex vivo
applications (Kumar et al., 2018). Moreover, SaCas9 recognizes
a considerably larger PAM sequence than SpCas9, NNGRRT,
which theoretically improves specificity. In fact, its application
in human cell lines revealed absent off-target activity, evaluated




Characteristics Off-target activity References
SpCas9 Most broadly used Cas9 Jinek et al., 2012
nCas9 Mutated SpCas9 D10A protein (deactivation of the RuvC
domain). Only cleaves one strand of DNA
1,500 × reduction of off-target effects Ran et al., 2013
dCas9-FokI Catalytically inactive Cas9 (D10A and H840A) fused with
FokI catalytic domain
No detectable off-targets Guilinger et al., 2014;
Tsai et al., 2014
eSpCas9 Structure-guided engineered Cas9 with the point-mutations
K848A, K1003A, and R1060A
Reduced off-target activity to non-detectable levels Slaymaker et al., 2016
SpCas9-HF1 Mutated version of SpCas9 (N497A, R661A, Q695A, and
Q926A)
Off-target activity not detected using GUIDE-seq Kleinstiver et al., 2016a
HypaCas9 Hyper-accurate Cas9 variant (N692A, M694A, Q695A, and
H698A mutations in the REC3 domain)
Better genome-wide specificity relative to both
SpCas9-HF1 and eSpCas9
Chen et al., 2017
Sniper-Cas9 Developed using a directed evolution approach Better specificity than the other high-fidelity
engineered variants
Lee et al., 2018
Cas9 orthologs
SaCas9 Ortholog derived from Staphylococcus aureus Recognizes a larger PAM sequence, which
theoretically improves specificity
Kumar et al., 2018
St1Cas9 Ortholog derived from Streptococcus thermophilus Evaluation by deep sequencing shows lower
off-target activity
Müller et al., 2016
St3Cas9 Ortholog derived from Streptococcus thermophiles Evaluation by deep sequencing shows lower
off-target activity
Müller et al., 2016
NmCas9 Ortholog derived from Neisseria meningitides Recognizes a larger PAM sequence and has lower
off-target activity compared to SpCas9
Lee et al., 2016
CjCas9 Ortholog derived from Campylobacter jejuni Lower off-target activity compared to SpCas9 Kim E. et al., 2017
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by deep sequencing (Wang et al., 2019). Cas9 proteins from
S. thermophilus, St1Cas9, and St3Cas9, specific for the PAM
sequences NNAGAAW and NGGNG, respectively, also show
lower off-target activity evaluated by deep sequencing (Müller
et al., 2016). The SpCas9 ortholog from N. meningitidis
(NmCas9) recognizes a larger PAM sequence, NNNNGHTT,
and has lower off-target activity than SpCas9 (Lee et al.,
2016). The C. jejuni Cas9 (CjCas9) is encoded by an even
smaller gene than SaCas9 (2.9 kb) has specificity for two PAM
sequences, NNNNACAC and NNNNRY, and lower off-target
activity compared to SpCas9 (Kim E. et al., 2017). Despite these
lower off-target activities, one should keep in mind that the
higher PAM complexity of the less used Cas9 orthologs reduces
the number of potential on-targets for a specific application.
Although Cas9 has dominated the gene-editing field, Cas12a
(initially described as CpfI), which was cloned from Francisella
novicida, has also been used as a tool. Cas12a and Cas9
belong to the class 2 CRISPR-Cas system, but the former
has distinctive features, namely a smaller size, the natural
use of a single RNA in the RNP complex, a T-rich PAM,
and the production of a staggered DSB instead of the blunt
break produced by Cas9 (Zetsche et al., 2015a). These breaks
were shown to be advantageous for HDR-mediated genome
editing (Moreno-Mateos et al., 2017). However, compared to
Cas9, the slightly more complex PAM and reports of a lower
efficiency (Lee et al., 2019) make it a less appealing tool.
More importantly for this review, two careful independent
analyses have shown that Cas12a introduces fewer off-targets
than Cas9 (Kim et al., 2016; Kleinstiver et al., 2016b; Yan
et al., 2017). Biochemical analyses suggest that this difference
probably occurs because Cas12a is less tolerant to mismatches
along most of the DNA target sequence than Cas9 (Strohkendl
et al., 2018). However, in vitro, Cas12a and Cas9 have been
shown to have strong nicking of DNA sequences containing
up to four mismatches, non-specific sequence nicking of
dsDNA when Cas12a is bound to a target DNA (Fu et al.,
2019; Murugan et al., 2020), and RNA-independent, non-
sequence specific DNA cleavage activities (Sundaresan et al.,
2017). Whether these effects also occur in vivo in Eukaryotic
cells is unclear, and nicks are typically less problematic
than DSBs, but the sequence non-specific editing would
be difficult to avoid using bioinformatic tools. Nevertheless,
the discovery of different CRISPR systems is still a highly




Chromatin accessibility conditions the efficiency of the CRISPR
system in gene editing; notably, the sgRNA binding is facilitated
in open chromatin regions (Kuscu et al., 2014; Wu et al., 2014),
and the state of the chromatin is often cell cycle-dependent.
In addition, HDR is active predominantly during the S and
G2 phases of the cell cycle. Thus, it is not surprising that
the cell cycle influences both the CRISPR efficiency and the
frequency of off-targets. The CRISPR-based adaptative immune
system in bacteria has never had to tackle the challenge of
DNA accessibility, as bacteria do not organize their genome
in nucleosomes and archaea, despite having histones, maintain
a relaxed structure allowing CRISPR to recognize phage DNA
even if integrated into its DNA. More importantly, the foreign
invading viral or phage DNA is highly accessible before
encapsulation, allowing an ample window of opportunity for
CRISPR-mediated immunity.
The efficiency of Cas9 editing is reduced in heterochromatic
regions (Jensen et al., 2017). Both binding and cleavage are
inhibited by nucleosomes (Horlbeck et al., 2016), particularly if
the PAM region is located within the nucleosome core (Hinz
et al., 2015; Isaac et al., 2016). This has been shown to occur both
in human and plant cells (Liu et al., 2019), but not in zebrafish
(Moreno-Mateos et al., 2015).
Therefore, quiescent cells or cells otherwise in a state of
compacted chromatin hamper the efficiency of targeting in a
way that may not be predictable by programs, as nucleosomes
sequester putative cleavage sites, particularly on mismatch hits
(Yarrington et al., 2018). On the other hand, the off-target effects
of Cas9 are greatly reduced in chromatin regions (Hinz et al.,
2015; Horlbeck et al., 2016), suggesting that the concerns raised
by results of cell-free methods used to compile a list of potential
off-target sites are greatly exaggerated, as many of these sites are
inaccessible in vivo (Kim and Kim, 2018).
Some effort is being put into altering the chromosome
accessibility to improve Cas9 activity in vivo. One strategy, proxy-
CRISPR, consists of using a catalytically dead SpCas9 to bind
to locations close to the target region, thus altering the local
chromatin structure and exposing previously inaccessible targets
to the nuclease activity of FnCas9, CjCas9, NcCas9, and FnCpf1;
this strategy was shown to improve editing efficiency on these
sites greatly and to lower the off-target activity (Chen et al.,
2017). However, this method requires the expression of two
CRISPR/Cas systems, making its in vivo application difficult.
Another method explores Cas9 orthologs fused to chromatin-
modulating peptides (CMPs), using a direct approach to remodel
the chromatin of the target sites. This method greatly improves
editing in refractory sites (Ding et al., 2019). However, for this
technique to be used in clinical trials, it has to be determined
if the presence of CMPs alters gene expression profiles. A more
recent approach uses histone deacetylase (HDAC) inhibitors to
promote chromatin accessibility for genome editing. Among the
HDAC inhibitors tested, vorinostat (suberoylanilide hydroxamic
acid) were the most efficient, raising both NHEJ- and HDR-
driven editing, with notable efficiency in the increase of HDR in
closed loci (Zhang et al., 2021). The observed increase of NHEJ
may hinder tailored gene editing applications, and should be
further analyzed.
Besides chromatin accessibility, the repair systems used
by Eukaryotic cells change during the cell cycle. HDR is
mainly active in mammalian cells during the S phase, when
DNA replication leads to the generation of endogenous repair
templates, and declines in the late-G2 phase. In contrast, the
NHEJ pathway occurs in all phases with special emphasis to G1
(Mao et al., 2008). Therefore, knocking in a DNA sequence tends
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to be more efficient during the S and G2 phases. Moreover, one
can expect that off-target DSBs generated in the presence of a
more proficient HDR pathway are repaired with an endogenous
sequence, thus decreasing the frequency of undesired mutations.
A way to increase the use of HDR to deal with the Cas9-
induced site-specific DSBs is to synchronize the cells to deliver
the Cas9 RNPs at a specific cell cycle phase. Cas9 RNP-mediated
editing starts 4 h after nucleofection and lasts for 24 h until the
RNPs are degraded (Kim et al., 2014). A careful study determined
at which point cells should be synchronized to maximize HDR
efficiency while reducing off-target effects. The most effective
cell synchronization treatment was Nocodazole, which blocks the
cells at the M phase. At this phase, cells have their DNA fully
replicated, and their nuclear membrane is broken down (Lin
et al., 2014). Researchers have also fused Cas9 to the N-terminal
region of Geminin protein, a substrate for the E3 ubiquitin
ligase complex APC/Cdh1. This strategy is particularly useful
because it does not require cell cycle inhibitors, as it uses the
cell cycle regulation machinery, marking Cas9 for degradation
via ubiquitination during the G1 phase, thus ensuring the proper
expression in time for the maximum HDR potential (Gutschner
et al., 2016). More recently, the discovery of bacteriophage
proteins that evade prokaryotic adaptive immunity, known as
anti-CRISPR proteins (reviewed in Maxwell, 2017), allowed for
a similar approach by fusing the anti-CRISPR protein AcrIIA4 to
the Chromatin licensing and DNA replication factor 1 (CDT1),
which ensures that DNA replication occurs only once per cell
division. Gene editing is deactivated by the anti-CRISPR during
the G1 and S phases, and during the G2 phase, because the
AcrIIA-CDT1 fusion is degraded, Cas9 becomes active. This
provided not only a decrease of the off-target effects but, at the
same time, a fourfold increase in HDR efficiency (Matsumoto
et al., 2020). The efficiency was higher than in previous studies
as the Cas9 is only inactivated but not degraded during the G1
phase.
A different strategy is to shift the balance of NHEJ vs. HDR by
disrupting key NHEJ players, either using molecular inhibitors,
short hairpin RNAs (shRNA), or the co-expression of Cas9 with
proteins that mediate the proteasomal degradation of ligase IV
(Chu et al., 2015). SCR7 is a ligase 4 inhibitor that has been
used in numerous studies with inconsistent results, suggesting
that its action is cell-type- or gene-dependent, making it a
poor general promotor of HDR for CRISPR (Bischoff et al.,
2020). A small molecule, RS-1, which stimulates RAD51 and
therefore HDR, improved the efficiency of targeted integrations
(Song et al., 2016); other small molecules have been shown to
promote HDR directly or indirectly by reducing NHEJ (reviewed
in Bischoff et al., 2020). The use of small molecules has also been
suggested to help attenuate the off-target problem. For example,
by inhibiting NHEJ, the frequency of off-targets is greatly reduced
(Zheng et al., 2020), whereas by boosting the HDR efficiency
with small molecules targeting can be successfully achieved in
diverse cell types with limited toxicity. These techniques open
new venues for therapeutic uses in cells that may be more
prone to off-target effects than iPSCs. The inhibition of NHEJ
could be, however, a source of greater genomic instability in
CRISPR applications.
OFF-TARGET ACTIVITY ACCORDING TO
CELL TYPE
The idea that the cell type might influence off-target activity is
based on both the evidence that the on-target effects vary with
cell type mostly due to chromatin condensation profiles and
DSB repair has different efficiencies depending on the cell type.
Using ChIP-seq to perform an unbiased genome-wide detection
of Cas9 binding sites for different sgRNAs, it was found that
open chromatin regions are enriched for off-target sites (Kuscu
et al., 2014; Wu et al., 2014). In addition, a pioneer study has
sparked the discussion by finding different potential off-target
binding in HeKaS3 vs. HEK293T cells. Off-target events might
depend on several factors beyond the DNA sequences, including
the cell type, DNA-RNA heteroduplex, R-loop expansion, and
so on (Duan et al., 2014). More importantly, for translational
applications of the technique, the off-target potential of Cas9 has
proven to be very limited in human iPSCs, where the DSB repair
pathways are working normally, when compared to regular cell
lines (Schwank et al., 2013; Smith et al., 2014; Veres et al., 2014).
Another cell-dependent mechanism studied for its effect on
Cas9 is CpG site methylation, a cell-type-specific epigenetic
mechanism. Despite an early study stating that CpG methylation
and chromatin accessibility have little effect on targeting (Hsu
et al., 2013), a subsequent analysis determined that CpG sites
are negatively correlated with Cas9 binding, particularly when
mismatches are present (Wu et al., 2014). We now know that
the off-target potential is cell-type based due to the DSB repair
system, the state of chromatin condensation, and the methylation
pattern of CpG sites.
OFF-TARGET ACTIVITY ACCORDING TO
DELIVERY TYPE
Two back-to-back publications showed that the delivery of RNPs
to target cells have reduced off-target effects compared to the
use of plasmids encoding Cas9 and sgRNA (Kim et al., 2014;
Ramakrishna et al., 2014). RNP delivery was performed using
cationic lipid-mediated delivery (lipofectamine) and positively
charged nanoparticles, leading to the same results. The RNP
binds and cleaves the chromosomal DNA after delivery and is
quickly degraded (Banas et al., 2020), leaving little time for the
less efficient off-target cleavage, whereas the plasmid expression
subsists for days before degradation. The ratio of off-target to
on-target mutations has been calculated to be 28-fold lower in
RNPs compared to the plasmid-based methods (Lu et al., 2019).
In addition, the RNP dose has been calculated to be lower in
the RNP complex transfection, resulting in lower cytotoxicity.
Lipofectamine delivery was confirmed to work in vivo in the
inner ear of mice (Zuris et al., 2015), and positively charged
nanoparticles (lipidoids) were also confirmed to deliver the
editing tools to the brain of mice (Wang et al., 2016).
Plasmid expression requires nuclear transport for RNA
transcription and mRNA export for translation. The expressed
Cas9 must then complex with the sgRNA and be transported into
the nucleus for the editing to occur. To complete these steps, it has
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been calculated that approximately 24 h are required (Shen et al.,
2019). This time can hinder some experiments dependent on
synchronized drug delivery or template donor delivery for HDR.
The delivery of Cas9 may also be in the form of RNA for direct
translation or protein (ready to work in a ribonucleoprotein
complex composed of Cas9 and sgRNA); RNA overcomes the risk
of integration and has poor stability compared to plasmid DNA.
Besides the delivery of Cas9 as a protein or as a plasmid, there
are several delivery systems available. These can be grouped as
viral vectors, physical (i.e., microinjection or electroporation),
or chemical methods, (cationic-lipid transfection and lipid
nanoparticles), ligand fusion tags, cell-penetrating peptides,
and gold nanoparticles, among others. The most common
viral vectors are adenoviruses, adeno-associated viruses, and
lentiviruses, since these are the ones approved for clinical trials
(Chakraborty, 2019).
Viral vectors may lead to unintended Cas9 genome
integration, raising important questions on the safety of clinical
trials. This topic remains a matter of debate (Chakraborty, 2019).
There is also the risk of immunogenicity both from the use of
the virus and the expression of the Cas9 protein. Even though
the safety of viral approaches has been addressed and improved,
the off-targets remain a concern due to the long-term exposure
caused by the delivery method; furthermore, the viral vectors
have limited packaging capacity.
An approach to avoid the risk of integration, immune
response, and the long-term Cas9 expression has been created
using a lentivirus-like particle (LVLP) encapsulating up to 100
copies of Cas9 mRNA per LVLP (Lu et al., 2019). Along the same
lines, to limit the expression of the nuclease and reach a broad
range of target cells, the Cas9/sgRNA RNP was recently packaged
into extracellular nanovesicles, leading to an enormous reduction
of off-targets compared to the plasmid-based delivery without
loss of on-target cleavage (Gee et al., 2020).
OFF-TARGETS IN OTHER
GENE-EDITING TECHNOLOGIES: ZFNs,
TALENs, AND BASE EDITORS
Precise gene editing of mammalian cells precedes CRISPR-
mediated editing by over 25 years, with the work of Capecchi
(Folger et al., 1984) and Smithies (Smithies et al., 1985),
who proved that homologous recombination could integrate
genetic material. Despite this breakthrough, the low efficiency
of integration requires a selection marker or the introduction
of a DSB to stimulate DNA repair. Meganucleases of microbial
origin capable of recognizing sequences of 14–40 bp can generate
DSBs, but the collection of sequences recognized by these
enzymes is limited. The ability to introduce a DSB in most
regions of the genome emerged with the invention of the
chimeric nucleases that use the cleavage domain of the type IIS
restriction enzyme FokI fused to modules of proteins that bind
to specific DNA sequence. The first of these tools to appear
were the Zinc Finger Nucleases (ZFN) (Geurts et al., 2009), in
which the DNA specificity is given by the association of several
finger domains, each contacting primarily with three specific
bp of DNA. In the second type of chimeric nucleases, known
as Transcription Activator-Like Effector Nucleases (TALENs)
(Miller et al., 2011), the DNA binding specificity is given by
the modules of transcription activator-like effectors of bacterial
origin, each recognizing a specific bp. ZFNs and TALENs were
shown to work with similar efficiencies in iPSCs (Hockemeyer
et al., 2009, 2011).
A simple Pubmed search shows that the CRISPR technology
is now vastly more popular within the research community than
the ZFN or TALEN ever were, but in a clinical setting, ultimately,
it is the safety of the method that will prevail. There is a recent
review comparing these two techniques with CRISPR-mediated
editing (Khalil, 2020). Thus, here we will compare the three
techniques exclusively concerning the off-targets. In principle,
both ZFN and TALEN should have a lower frequency of off-
targets than the original CRISPR/Cas9 technique because the
FokI cleavage domain works as a dimer, which requires the
targeting of two neighboring regions in the genome to produce
a DSB, thus vastly decreasing the number of off-targets, as
explained in a previous section. However, the comparison is not
straightforward, due to the different complexity of the sequences
targeted by each strategy and the different biochemistry of
RNA:DNA and protein:DNA interactions. Nevertheless, both for
the chimeric nucleases and CRISPR, increasing the interaction
length with the target sequence did not improve the specificity
or efficiency (Ran et al., 2013; Yan et al., 2013).
ZFN off-targets with up to three mutations relative to
the canonical target sequence were identified using in vitro
cell-free strategies and confirmed in cell lines and zebrafish
(Gupta et al., 2011; Pattanayak et al., 2011). A thorough study
using the unbiased IDLV-based methods to tag ZFN-dependent
DSBs revealed several off-targets, but overall that ZFNs are
highly specific, particularly when obligate heterodimeric FokI
domains are used. In a TALEN-engineered mouse, no off-targets
were detected, although only low-resolution and limited direct
methods were used (Gabriel et al., 2011). And a hybrid strategy
combining a ZFN and a TALEN seems to improve specificity
even further (Yan et al., 2013). Unfortunately, properly controlled
studies directly addressing the off-targets produced by CRISPR
and the chimeric nucleases are scarce. In a goat genome editing
project, CRISPR/Cas9 was reported to have introduced more off-
targets than a TALEN approach for the same editing (Zhang
et al., 2019); in another set of experiments using IDLV tagging
of DSBs, the frequency of off-targets generated by Cas9 and
TALENs were directly compared and the results revealed that
three different TALENs generated no off-targets, whereas three
of six Cas9 RNPs had detectable off-target activity (Wang et al.,
2015). Interestingly, besides detecting the known tolerance for
a few mismatches, the authors found patterns suggesting that a
single-base bulge formed between the sgRNA and the genomic
target could also be tolerated. Thus, paradoxically, the data
suggest that the wild-type SpCas9 that has been the focus of so
much attention introduces more off-targets than the TALENs
and, as mentioned above, Cas12a.
The dCas9 (catalytically null version of Cas9) has been fused
to many proteins to become a molecular swiss-army knife capable
of driving different enzymatic activities or useful structural
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properties (e.g., fluorescent proteins) to precise locations in the
genome. Some of these strategies have also transformed the
original Cas nuclease into base editors by fusing a dCas9 or a
Cas nickase with natural cytosine base editors (capable of C-to-T
conversions) or engineered adenine base editors (that catalyze
A-to-G conversions) to generate single-base editors capable of
editing close to a third of the annotated human pathogenic alleles
(reviewed in Anzalone et al., 2020). The absence of a potentially
dangerous DSB during the editing process is an attractive feature
of these tools. However, they use deaminases that have been
associated with mutational signatures in several types of cancers.
A study in mouse embryos revealed that CRISPR-Cas9 and the
adenine base editor had a frequency of mutations close to the
spontaneous mutation rate; in contrast, cytosine base editing
induced single nucleotide variants at more than 20-fold higher
frequencies (Zuo et al., 2019). Thus, base editors have been fine-
tuned in recent years through the titration of the expression
levels, the use of a “high-fidelity” Cas9 partner (e.g., Rees et al.,
2017; Hu et al., 2018; Lee et al., 2018; Doman et al., 2020) or
the use of deaminases that preferentially deaminate cytidines in
specific motifs (e.g., Gehrke et al., 2018). Nevertheless, besides
the Cas9-dependent off-targets, these tools also produce Cas9-
independent deamination events that are difficult to measure
because of their random nature and rarity. This problem has been
addressed independently by two groups, and these efforts include
a thorough study of 153 deaminase domains to isolate and further
engineer those with the lowest Cas9-independent off-target DNA
deamination (Doman et al., 2020; Yu et al., 2020).
CONCLUSION AND FUTURE
PERSPECTIVES
Off-targets are not a problem for basic research using cell lines
and animal models. It is sufficient to adopt the experimental
design developed several years ago for shRNA studies to ensure
that the observed effect is due to the on-target edition. In other
words, if two clones obtained with different sgRNAs have the
same phenotype, it is very unlikely that the effect is due to
a technical artifact because the two guides will have different
constellations of off-targets. In addition, rescue experiments are
also possible and could be reassuring. It is only in the context
of the ongoing clinical trials in humans using somatic cells
and in the possible future edition of the germline that the off-
targets remain a problem, although not the only one. That is
the motivation fueling the many approaches to attenuate the
off-target problem.
Two tragic stories haunt the field of gene therapy. Mr. Jesse
Gelsinger died in 1999 from an exacerbated innate immune
response to an adenoviral vector carrying a gene to correct his
partial deficiency of ornithine transcarbamylase (Wilson, 2009).
Not long after, out of 20 children suffering from X-Linked Severe
Combined Immunodeficiency who were treated by gene therapy
in two independent trials, five developed T cell leukemia, which
would prove fatal in one case (Cavazzana et al., 2016); all cases
resulted from the insertion of the retroviral vector carrying the
correct form of the γc-encoding gene near tumor-promoting
genes. The field eventually recovered from these early failures
by developing safer vectors and protocols, and also novel
technologies, such as CRISPR, that restore the correct DNA
sequence and proper regulation. CRISPR gene editing is now
regarded as a much safer gene therapy than the crude pioneering
viral-based therapies, which were not gene editing approaches.
However, any tragic clinical outcome associated with these novel
technologies and whether the prior risk-benefit analyses need to
be recalibrated.
CRIPSR-mediated gene editing has been described in models
of Duchene muscular dystrophy (DMD), a genetic disease caused
by mutations in the dystrophin gene (DMD), which encodes a
cytoskeletal protein essential for muscle cell membrane integrity
(Zhang et al., 2017). Cas12a-mediated gene editing was first
employed in DMD patient-derived iPSCs and also in a murine
model of the disease, with a mutation in Exon 51 of theDMD gene
that generates a premature stop codon. The Cas12a-mediated
gene editing rescued the disease phenotype in both models.
The off-target activity was assessed by the T7 Endonuclease
assay in 10 potential off-target sites, predicted by Cas-OFFinder,
with no detected activity (Zhang et al., 2017). In a follow-up
study, the same group applied the same strategy in a canine
model of DMD in which the delivery of Cas9:sgRNA was
done with adeno-associated viruses, via intramuscular injection
(Amoasii et al., 2018). The disease phenotype was rescued with
the application of CRISPR-mediated gene editing. Three off-
target sites in coding regions were predicted using the MIT
CRISPR design tool and deep sequencing of those sequences was
performed. There were no genetic alterations in the predicted
off-target sites (Amoasii et al., 2018). CRISPR/Cas9-based gene
editing has been used in several other animal models of disease,
particularly the murine ones. The off-targets have been measured
using biased methods and Sanger sequencing of a small number
of cloned amplicons from a few potential off-targets, such as in
a model of Huntington’s disease (Monteys et al., 2017), biased
methods and deep sequencing of amplicons from a modest
number of potential off-targets, such as in a murine genetic
model of amyotrophic lateral sclerosis (Gaj et al., 2017), and
biased and unbiased methods (whole-exome and whole-genome
sequencing), such as in a study of an Alzheimer’s disease model
(Park et al., 2019). The overall picture is that off-targets and
chromosomal rearrangements have not been detected at alarming
frequencies in any CRISPR/Cas9-based gene editing to correct
genetic deficiencies in animal models of disease. However, the
methodology of off-target detection and quantification has not
been standardized across these studies.
It is worth keeping in mind that clinical applications of the
CRISPR technology in humans started a few years ago, even
though the technique is still being perfected. In February 2019,
the first report of cancer patients treated with CAR-T cells that
had been edited using a combination of a retroviral vector and
three CRISPR-knocked-out genes was published (Stadtmauer
et al., 2020); although the immunotherapy itself did not provide
complete cancer treatment, the engineered cells were well-
tolerated. Another CRISPR technology application in the clinic
was a phase I clinical trial of edited T cells, where the goal was to
disrupt the PD-1 gene to overcome the high expression of PD-L1
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in the malignant cells of refractory non-small-cell lung cancer
(Lu et al., 2020). In that study, the off-targets were determined
using Cas-OFFinder and indels in those regions were detected
by NGS. The off-target mutational frequency was 0.05% in
18 determined off-target sites, which was considered to be
safe. Moreover, a CRISPR/Cas9 application in the treatment of
the Transfusion-dependent ß-thalassemia and sickle cell disease
(both severe monogenic diseases) was reported in January
of 2021 (Frangoul et al., 2021). CD34+ hematopoietic stem
cells were transfected with a Cas9:sgRNA complex targeting
the BCL11A erythroid-specific enhancer. A total of 223 off-
target sites were scanned, and no evidence of off-target activity
was detected. Although these reports suggest that the off-
targets may not be a problem for clinical applications, three
potential technical limitations should be kept in mind. First,
any long-term side-effects of the CRISPR editing, such as
a slow-growing cancer, will remain undetectable for some
time. Second, even when amplicon-based and hybridization
capture steps are used to enrich the target genomic regions
to be analyzed by NGS, this technique has a resolution limit,
particularly when bulk cell populations are analyzed. Third,
whole-genome sequencing of large collections of small pools
of cells to evaluate in an unbiased way the frequency of off-
targets is currently not possible to implement on a routine
basis in clinical settings. Notwithstanding these limitations, there
are over 60 ongoing clinical trials using CRISPR technology
to treat more than 30 different diseases (see CRISPR News
Medicine1). Standardized measures of off-target analysis in these
trials would be welcome.
The many ingenious strategies developed over the last 8 years
to decrease the frequency of off-targets that we have described
have not exhausted the field. Recently, CRISPR GUARD was
reported, a technique based on the targeting of the off-targets
by RNPs with short RNAs that do not allow nuclease activity
but can outcompete the on-target guide RNA at selected off-
targets (Coelho et al., 2020). Although the practicability of this
technique remains to be tested, it illustrates how truly novel
ideas keep emerging. Such ingenuity will be required to tackle
several remaining challenges, including: (1) the generation of
improved in silico tools that integrate what is known about the
tolerance for mismatches but also on single-base bulges and all
1 https://crisprmedicinenews.com/clinical-trials/
the epigenetic features that influence the chances of a hit in
an off-target; (2) more detailed and cell-specific analyses using
unbiased methods of the off-targets in cells with therapeutic
potential, such as human CD8 T cells and iPSCs of different
sources; (3) a better integration of the strategies to reduce off-
targets generated at several fronts and the implementation of
standards to facilitate comparisons across different studies. This
third point seems crucial. Although platforms such as Addgene
have facilitated the sharing of molecular tools, it seems that the
progress in the field has been delayed by the failure to implement
two strategies. First, using the same cell line or animal models,
engineered with reporters or not, and common protocol and
readouts to compare the results of the different tools would
provide quantitative comparisons that would quickly identify the
best tools across different platforms. Second, despite the quest for
innovation and commercial interests do not create incentives to
fully explore the combination of methodologies already described
that could lead to cumulative or synergistic decreases in the
frequency of off-targets.
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